Quantum-Si Incorporated filings document the formal disclosures of a Nasdaq-listed proteomics technology company developing single-molecule protein sequencing systems. Form 8-K reports furnish financial results, business updates, Regulation FD presentations and material agreements tied to the company’s operations and capital markets activity.
The filing record also covers annual-meeting proxy matters, board and compensation governance, executive and equity-award disclosure, Class A common stock, and redeemable warrants listed under QSIAW. Material-event filings document sales-agreement and shelf-registration disclosures for potential Class A common stock issuance, as well as lease-related settlement and termination matters.
Quantum-Si Incorporated subject of a Form 144 notice relating to proposed sales of Class A Common Stock by Morgan Stanley Smith Barney LLC. The filing lists 8,655 shares and references prior restricted stock unit vesting of 21,676 units on 03/15/2024.
The notice also records sales in the past three months on 12/22/2025 of 8,627 shares. The filing is a broker-serviced resale notice under the SEC resale rules.
Quantum-Si Incorporated filed a Form 144 reporting an intended sale of Class A Common Stock through Morgan Stanley Smith Barney LLC. The filing lists 59,609 shares tied to a Restricted Stock Unit Vesting event dated 03/15/2024. It also reports prior sales of 23,707 shares on 12/22/2025 as securities sold during the past three months. The broker listed is Morgan Stanley Smith Barney LLC with an address at 1 New York Plaza, New York, NY.
Quantum-Si Inc reported that Chief Financial Officer Jeffry R. Keyes received new equity awards. He was granted stock options for 780,847 shares of Class A common stock at an exercise price of $0.976 per share, expiring on March 12, 2036.
Keyes was also granted 652,803 restricted stock units, increasing his direct common stock holdings to 1,816,000 shares after the grant. The RSUs vest in four equal annual installments beginning on April 20, 2027, while the option vests in equal quarterly installments starting on June 20, 2026, in each case subject to his continued service.
Quantum-Si Inc Chief Product Officer John S. Vieceli received new equity awards. On March 12, 2026, he was granted options to buy 468,508 shares of Class A common stock at an exercise price of $0.976 per share, vesting in equal quarterly installments beginning on June 20, 2026 until fully vested, subject to continued service.
He also received 391,681 restricted stock units, each representing one share of common stock upon vesting, on the same vesting schedule starting June 20, 2026. Following these awards, Vieceli directly holds 1,192,654 shares of Class A common stock. These are compensation-related grants rather than open-market purchases or sales.
Quantum-Si Inc President & CEO Jeffrey Alan Hawkins reported equity compensation awards rather than open-market trades. He received a stock option covering 1,561,695 shares of Class A common stock at an exercise price of $0.976 per share, expiring on March 12, 2036. The option vests in equal quarterly installments beginning on June 20, 2026, subject to continued service. He also received 1,305,606 restricted stock units, each representing one share of common stock, which vest in four equal annual installments starting on April 20, 2027, subject to continued service. Following the RSU grant, his direct holdings of Class A common stock increased to 3,883,624 shares.
Quantum-Si Inc reported that its General Counsel and Corporate Secretary, Christian LaPointe, received new equity awards. He was granted 261,121 shares of Class A common stock in the form of restricted stock units and a stock option for 312,339 shares at an exercise price of $0.976 per share. Both the RSUs and the option vest in equal quarterly installments beginning on June 20, 2026, subject to continued service. Following these awards, LaPointe directly owns 1,209,976 shares of Class A common stock.
Quantum-Si Inc director Charles R. Kummeth reported an open-market purchase of 500,000 shares of Class A common stock on March 5, 2026. The weighted average purchase price was $0.9196 per share, with individual trades executed between $0.8906 and $0.9735 per share. Following this transaction, he directly holds 855,000 shares of Quantum-Si common stock.
Quantum-Si Inc director Paula Dowdy purchased Class A common stock in an open-market transaction. On March 5, 2026, she bought 109,890 shares at a weighted average price of $0.9505 per share, and held 269,107 shares directly after the trade.
The footnote explains that the $0.9505 figure is a weighted average, with actual purchase prices ranging from $0.9051 to $0.9730 per share. Detailed price breakdowns are available upon request from regulators, the company, or its security holders.
Quantum-Si Incorporated is an early-stage life sciences technology company focused on proteomics, aiming to make single-molecule protein sequencing widely accessible. It has developed its Platinum and higher-priced Platinum Pro next-generation protein sequencing instruments, sold with proprietary library preparation and sequencing kits plus Platinum Analysis Software.
The company targets research-use-only applications today, positioning its platform as a lower-cost, automated alternative and complement to legacy mass spectrometry and affinity-based methods. Management describes a large addressable market within a broader proteomics opportunity and plans to drive recurring consumables revenue from a growing installed base. A major roadmap milestone is the Proteus platform, expected to launch by the end of 2026 with much higher feature density and automation. Key risks include continued net losses and funding needs, potential delays or underperformance of Proteus, dependence on single-source contract manufacturers and semiconductor processes, evolving data, privacy and healthcare regulations, and governance factors such as controlled-company status, dual-class stock and the need to maintain Nasdaq listing.
Quantum-Si Incorporated reported wider full-year losses while preparing for its next-generation Proteus platform launch. For 2025, revenue was $2.4 million, with gross profit of $1.2 million and a gross margin of 47%. The company posted a 2025 net loss of $101.3 million, similar to the prior year, but reduced adjusted operating expenses to $86.3 million from $99.0 million.
In the fourth quarter of 2025, revenue was $0.5 million with a 27% gross margin and a net loss of $17.6 million. Management highlighted significant cost discipline and one-time litigation charges of $18.7 million during 2025. As of December 31, 2025, cash, cash equivalents and marketable securities totaled $215.8 million, which the company believes funds operations into the second quarter of 2028.
For 2026, Quantum-Si issued guidance for revenue of approximately $1.0 million, adjusted total operating expenses of $98.0 million or less, and total cash usage of $93.0 million or less. The company expects 2026 to be a transition year, intentionally moderating revenue as it embeds upgrade credits and placement programs to support a stronger commercial launch of the Proteus system, which has a list price of $425,000 and is targeted for launch by the end of 2026.